Sunday, 05 December 2021

Jubilant Pharmova posts consolidated PAT of Rs 213.90 Cr in Q4FY21

04 June 2021 | News

Reports a total income of Rs 1586.47 crores

The Board of Jubilant Pharmova has approved the financial results for the quarter ended March 31, 2021. The company has reported total income of Rs 1586.47 crores during the period ended March 31, 2021 as compared to Rs 1774.93 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs 213.90 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs 309.93 crores for the period ended December 31, 2020. It has reported EPS of Rs 13.43 for the period ended March 31, 2021 as compared to Rs 19.46 for the period ended December 31, 2020.

In the year ended quarter FY 20-21, the company has reported total income of Rs 6116.18 crores during the 12 months ended March 31, 2021 as compared to Rs 6013.20 crores during the 12 months ended March 31, 2020.

The company has posted net profit / (loss) of Rs 835.87 crores for the 12 months ended March 31, 2021 as against net profit / (loss) of Rs.898.24 crores for the 12 months ended March 31, 2020. It has reported EPS of Rs.52.48 for the 12 months ended March 31, 2021 as compared to Rs.56.39 for the 12 months ended March 31, 2020.

Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and MD, Jubilant Pharmova said, "With the demerger of LSI business into Jubilant Ingrevia effective February 1, 2021, the company’s consolidated results for Q4’FY21 include only one month of LSI business and consolidated results for FY21 include only ten months of LSI business. For FY21 our continuing operations, despite COVID-19 challenges, revenues were stable due to a diverse range of businesses. CDMO and Generics grew though we saw impact on radiopharma and had production impact at the Nanjangud API plant."

They further said, "Specialty pharma segment especially radiopharma was impacted due to COVID-19 and competition in radiopharma. In radiopharmaceuticals, we are expanding our product pipeline with strategic partnerships and have begun to execute a detailed turnaround plan of radiopharmacy business. CMO and generics delivered strong growth and we plan to expand capacity in CMO and enhance number and complexity of products under development in generics."

They added, "We are doubling our chemistry research capacity that should commission by Q2’FY22. Despite COVID-19 related lockdowns, we have been able to ensure continuity in most of our manufacturing operations across all business segments while at the same time ensuring safety of our employees.”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

//Survey Form JS Starts //Survey Form JS Ends